Segment Information

9 Months Ended

Jun. 30, 2024

Segment Reporting [Abstract]

Segment Information

12. Segment Information

Segment revenue, operating (loss) income, and depreciation and amortization were as follows:

	Three Months Ended June 30,						Nine Months Ended June 30,
(In thousands)	2024			2023			2024			2023
Revenue:
Medical Device	$	23,383		$	46,014		$	71,754		$	84,739
In Vitro Diagnostics		6,958			6,469			21,097			19,875
Total revenue	$	30,341		$	52,483		$	92,851		$	104,614
Operating (loss) income:
Medical Device	$	(2,288	)	$	21,777		$	(2,210	)	$	7,483
In Vitro Diagnostics		3,153			2,866			9,633			9,450
Total segment operating income		865			24,643			7,423			16,933
Corporate		(6,234	)		(3,231	)		(12,455	)		(9,333	)
Total operating (loss) income	$	(5,369	)	$	21,412		$	(5,032	)	$	7,600
Depreciation and amortization:
Medical Device	$	1,958		$	1,997		$	5,928		$	5,883
In Vitro Diagnostics		92			78			285			230
Corporate		76			76			342			252
Total depreciation and amortization	$	2,126		$	2,151		$	6,555		$	6,365

The Corporate category includes expenses that are not fully allocated to the Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to administrative corporate functions, such as executive management, corporate accounting, information technology, legal, human resources and Board of Directors. Corporate may also include expenses, such as litigation and merger-and-acquisition-related costs, which are not specific to a segment and thus not allocated to the reportable segments.

Asset information by segment is not presented because the Company does not provide its chief operating decision maker assets by segment, as the data is not readily available.